Skip to main content

Table 1 Demographic and clinical characteristics of case patients infected with IRAB, compared with non-infected control patients

From: A gloves-associated outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit in Guangdong, China

Characteristica Cases (n = 11) Controls (n = 14) P value
 Age (years) 65.09 ± 12.65 63.86 ± 14.33 0.824
 Gender, male (%) 5 (45.46) 5 (35.71) 0.622
 Prior hospital stay (<1 year) 3 (27.27) 2 (14.29) 0.420
 Length of stay in ICU (days) 6 (3–25) 11 (2.75–25.75) 0.784
APACHE II score upon ICU admission 21.82 ± 7.13 21.50 ± 8.04 0.919
SOFA score upon ICU admission 6.55 ± 3.14 7.00 ± 6.49 0.762
Primary ICU admission diagnosis    
  Chronic pulmonary disease 8 (72.72) 4 (28.57) 0.028
  Pneumonia 8 (72.72) 8 (57.14) 0.42
  Diabetes mellitus 1 (9.09) 2 (14.28) 0.692
  Hypertension 2 (18.18) 5 (35.71) 0.332
  Malignancy 2 (18.18) 3 (21.42) 0.84
Surgery procedure (<30 days) 1 (9.09) 5 (35.71) 0.122
 Antibiotic classesb    
  Carbapenem 7 (63.63) 6 (42.86) 0.302
  Penicillins 3 (27.27) 6 (42.56) 0.420
  Piperacillin/tazobactam 5 (45.45) 6 (42.86) 0.897
  Cefepime 7 (63.63) 6 (42.86) 0.302
  Fluoroquinolones 3 (27.28) 3 (21.42) 0.734
  Glycopeptide 6 (54.54) 8 (57.14) 0.716
  Antifungal 4 (36.36) 4 (28.57) 0.678
 ICU procedures    
  Ventilator 11 (100) 14 (100) --
  Blood transfusion 5 (45.45) 7 (50) 0.821
  Hemodialysis 0 (0) 4 (28.57) 0.053
  Nasogastric tube 11 (100) 12 (85.71) 0.191
  Venous central catheter 10 (81.82) 13 (92.86) 0.859
  Peripheral venous catheter 11 (100) 13 (92.86) 0.366
  Arterial catheter 4 (36.36) 6 (42.86) 0.742
  Urinary catheter 11 (100) 14 (100) --
 Outcome    
  28-day mortality 3 (27.27) 2 (14.29) 0.420
  Hospital mortality 6 (54.56) 3 (21.42) 0.032
  1. aAll data are presented as the number, with the percentage in parenthesis, with the exception of age, APACHE II score, and SOFA score, which are presented as mean ± standard deviation. Length of ICU stay was presented as median (interquartile range).
  2. bCase group: used within 30 days before the first IRAB isolate was discovered and the antibiotics had been used for at least 72 h. Control group: antibiotics had been used in the ICU for at least 72 h.